DE69839992D1
(de)
|
1997-03-21 |
2008-10-23 |
Chugai Pharmaceutical Co Ltd |
Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
|
US6395511B1
(en)
|
1998-11-27 |
2002-05-28 |
Darwin Discovery, Ltd. |
Nucleic acids encoding a novel family of TGF-β binding proteins from humans
|
BR0014486A
(pt)
*
|
1999-10-04 |
2002-09-17 |
Chiron Corp |
Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
AU1344102A
(en)
|
2000-10-12 |
2002-04-22 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
EP2340849A1
(en)
*
|
2001-05-30 |
2011-07-06 |
Genentech, Inc. |
Anti-NGF antibodies for the treatment of various disorders
|
AU2006202688B2
(en)
*
|
2001-05-31 |
2009-01-22 |
Genentech, Inc. |
Stable liquid formulations of antibodies
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
US20080026068A1
(en)
*
|
2001-08-16 |
2008-01-31 |
Baxter Healthcare S.A. |
Pulmonary delivery of spherical insulin microparticles
|
PT1441589E
(pt)
*
|
2001-11-08 |
2012-08-13 |
Abbott Biotherapeutics Corp |
Formulação farmacêutica líquida estável de anticorpos igg
|
WO2003100008A2
(en)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Neutralizing human anti-igfr antibody
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
CN1671741A
(zh)
*
|
2002-06-21 |
2005-09-21 |
拜奥根Idec公司 |
浓缩抗体的缓冲剂制剂及其使用方法
|
US20040033228A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
WO2004060343A1
(en)
*
|
2002-12-31 |
2004-07-22 |
Nektar Therapeutics |
Antibody-containing particles and compositions
|
DK1599222T3
(da)
*
|
2003-01-08 |
2009-04-27 |
Novartis Vaccines & Diagnostic |
Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
|
US20040208870A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
BRPI0403964B8
(pt)
|
2003-04-04 |
2021-05-25 |
Genentech Inc |
formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
|
GB2401040A
(en)
*
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
NZ544618A
(en)
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
BRPI0411852A
(pt)
|
2003-06-27 |
2006-05-23 |
Abgenix Inc |
anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
|
DE10348550A1
(de)
*
|
2003-10-20 |
2005-06-16 |
Hexal Biotech Forschungsgmbh |
Stabile wässrige G-CSF-haltige Zusammensetzungen
|
WO2005042024A1
(en)
*
|
2003-11-04 |
2005-05-12 |
Lek Pharmaceuticals D.D. |
Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
JPWO2005063291A1
(ja)
*
|
2003-12-25 |
2007-07-19 |
麒麟麦酒株式会社 |
抗体を含有する安定な水性医薬製剤
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
EP1765294B1
(en)
|
2004-05-12 |
2008-09-24 |
Baxter International Inc. |
Nucleic acid microspheres, production and delivery thereof
|
WO2005112893A1
(en)
*
|
2004-05-12 |
2005-12-01 |
Baxter International Inc. |
Microspheres comprising protein and showing injectability at high concentrations of said agent
|
WO2005112885A2
(en)
*
|
2004-05-12 |
2005-12-01 |
Baxter International Inc. |
Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
|
US8728525B2
(en)
*
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
JP4994232B2
(ja)
*
|
2004-07-23 |
2012-08-08 |
ジェネンテック, インコーポレイテッド |
抗体又はその断片の結晶化
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
TW200621282A
(en)
*
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
US7655758B2
(en)
|
2004-08-17 |
2010-02-02 |
Regeneron Pharmaceuticals, Inc. |
Stable liquid IL-1 antagonist formulations
|
US7572893B2
(en)
*
|
2004-08-17 |
2009-08-11 |
Regeneron Pharmaceuticals, Inc. |
IL-1 antagonist formulations
|
US20060051347A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
LT2586459T
(lt)
*
|
2005-03-25 |
2017-09-25 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonisto kompozicijos
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
CA2604393A1
(en)
*
|
2005-04-15 |
2006-10-26 |
Schering Corporation |
Methods and compositions for treating or preventing cancer
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
MX2007014148A
(es)
|
2005-05-19 |
2008-01-11 |
Amgen Inc |
Composiciones y metodos para incrementar la estabilidad de anticuerpos.
|
ES2776657T3
(es)
|
2005-06-14 |
2020-07-31 |
Amgen Inc |
Formulaciones de proteínas autotamponantes
|
NZ567685A
(en)
*
|
2005-11-01 |
2011-07-29 |
Wyeth Corp |
A Factor IX formulation for injection comprising sodium chloride
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
JP5405122B2
(ja)
*
|
2005-12-21 |
2014-02-05 |
ワイス・エルエルシー |
低粘度のタンパク質製剤およびその用途
|
WO2007074880A1
(ja)
*
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体含有安定化製剤
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
AU2007212147A1
(en)
*
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
ES2654040T3
(es)
|
2006-03-31 |
2018-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
|
EP2021030A2
(en)
*
|
2006-04-21 |
2009-02-11 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
LT2944306T
(lt)
|
2006-06-16 |
2021-02-25 |
Regeneron Pharmaceuticals, Inc. |
Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
|
MX2009001226A
(es)
*
|
2006-08-04 |
2009-03-20 |
Baxter Int |
Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
|
EP2094247B1
(en)
|
2006-10-20 |
2022-06-29 |
Amgen Inc. |
Stable polypeptide formulations
|
CA2667989A1
(en)
*
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
CA2667894A1
(en)
*
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
CL2008000058A1
(es)
*
|
2007-01-09 |
2008-05-23 |
Wyeth Corp |
Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
|
BRPI0809112A2
(pt)
*
|
2007-03-22 |
2014-08-26 |
Imclone Llc |
Formulações estáveis de anticorpos
|
JP5779350B2
(ja)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
抗体代替軽鎖配列を含む構築物およびライブラリー
|
NZ598881A
(en)
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
JP5456658B2
(ja)
*
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
CN101686939B
(zh)
*
|
2007-04-17 |
2013-03-27 |
巴克斯特国际公司 |
用于肺部投送的核酸微粒
|
CN104887620A
(zh)
|
2007-05-02 |
2015-09-09 |
诺沃—诺迪斯克保健股份有限公司 |
包括芳香族防腐剂和抗氧化剂的高浓度因子vii多肽制剂
|
WO2008143867A1
(en)
*
|
2007-05-15 |
2008-11-27 |
Stryker Corporation |
Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
|
RU2009148891A
(ru)
*
|
2007-06-01 |
2011-07-20 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Очистка иммуноглобулина
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
JP5469077B2
(ja)
*
|
2007-11-12 |
2014-04-09 |
アレス トレーディング ソシエテ アノニム |
Taci−免疫グロブリン融合タンパク質のための調製物
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
US11197916B2
(en)
|
2007-12-28 |
2021-12-14 |
Takeda Pharmaceutical Company Limited |
Lyophilized recombinant VWF formulations
|
NZ586383A
(en)
|
2007-12-28 |
2012-11-30 |
Baxter Int |
Recombinant vwf formulations
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
*
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
EP2285401A1
(en)
*
|
2008-05-23 |
2011-02-23 |
Novo Nordisk Health Care AG |
Low viscosity compositions comprising a pegylated gla-domain containing protein
|
WO2009141418A1
(en)
*
|
2008-05-23 |
2009-11-26 |
Novo Nordisk A/S |
Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
|
WO2010000721A1
(en)
*
|
2008-06-30 |
2010-01-07 |
Novo Nordisk A/S |
Anti-human interleukin-20 antibodies
|
BRPI0919693A2
(pt)
|
2008-10-21 |
2020-08-11 |
Baxter Healthcare S.A |
formulação farmacêutica estável liofilizada
|
WO2010062896A1
(en)
*
|
2008-11-28 |
2010-06-03 |
Abbott Laboratories |
Stable antibody compositions and methods for stabilizing same
|
PL2373681T3
(pl)
|
2008-12-10 |
2017-07-31 |
Glaxosmithkline Llc |
Kompozycje farmaceutyczne albiglutydu
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US10005830B2
(en)
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
WO2011026948A1
(en)
|
2009-09-03 |
2011-03-10 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
EP2403874A1
(en)
|
2009-03-06 |
2012-01-11 |
Genentech, Inc. |
Antibody formulation
|
RU2560701C2
(ru)
*
|
2009-05-04 |
2015-08-20 |
Эббви Байотекнолоджи Лтд. |
Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
BR122012017389B8
(pt)
*
|
2009-07-01 |
2021-06-22 |
Fresenius Medical Care Holdings Inc |
dispositivo para administração de fármacos
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
JP2013501058A
(ja)
*
|
2009-08-04 |
2013-01-10 |
ジェネンテック, インコーポレイテッド |
低減された粘性を有する濃縮ポリペプチド製剤
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
US8454956B2
(en)
*
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
KR101436219B1
(ko)
|
2009-10-26 |
2014-09-01 |
에프. 호프만-라 로슈 아게 |
글리코실화된 면역글로불린의 제조 방법
|
EP2494356B1
(en)
*
|
2009-10-26 |
2017-03-15 |
Genentech, Inc. |
Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
|
MX2012009755A
(es)
*
|
2010-02-26 |
2012-09-12 |
Novo Nordisk As |
Composiciones que contienen anticuerpo estable.
|
SG10201502587SA
(en)
|
2010-03-01 |
2015-06-29 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
WO2011109365A2
(en)
*
|
2010-03-01 |
2011-09-09 |
Progenics Pharmaceuticals, Inc. |
Concentrated protein formulations and uses thereof
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
PL2550018T3
(pl)
|
2010-03-22 |
2019-08-30 |
F.Hoffmann-La Roche Ag |
Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
|
EP2566510A1
(en)
*
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
US8691763B2
(en)
|
2010-05-04 |
2014-04-08 |
Glaxosmithkline Llc |
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
|
EA027039B1
(ru)
*
|
2010-05-14 |
2017-06-30 |
Эмджен Инк. |
Композиции с высокой концентрацией антител
|
US20130136733A1
(en)
|
2010-05-28 |
2013-05-30 |
Novo Nordisk A/S |
Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
|
AU2011274363A1
(en)
*
|
2010-07-02 |
2013-01-24 |
Medimmune, Llc |
Antibody formulations
|
EP3351559A3
(en)
|
2010-11-08 |
2018-10-31 |
F. Hoffmann-La Roche AG |
Subcutaneously administered anti-il-6 receptor antibody
|
CA2815689C
(en)
|
2010-11-11 |
2016-11-22 |
Abbvie Biotechnology Ltd. |
Improved high concentration anti-tnf.alpha. antibody liquid formulations
|
TR201802772T4
(tr)
|
2010-11-17 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
|
WO2012101253A1
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
WO2012106174A1
(en)
|
2011-01-31 |
2012-08-09 |
Fresenius Medical Care Holdings, Inc. |
Preventing over-delivery of drug
|
WO2012108984A1
(en)
|
2011-02-08 |
2012-08-16 |
Fresenius Medical Care Holdings, Inc. |
Magnetic sensors and related systems and methods
|
WO2012118903A2
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
CN103517920B
(zh)
|
2011-03-25 |
2018-04-17 |
安进公司 |
抗硬化蛋白(sclerostin)抗体晶体及其制剂
|
KR20140018966A
(ko)
*
|
2011-04-07 |
2014-02-13 |
글락소스미스클라인 엘엘씨 |
점도가 감소된 제제
|
JP2014510152A
(ja)
*
|
2011-04-07 |
2014-04-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
粘度が低減された処方物
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
PT2739311T
(pt)
|
2011-08-04 |
2018-03-26 |
Amgen Inc |
Método para tratamento de defeitos de lacunas ósseas
|
US9630988B2
(en)
|
2011-09-01 |
2017-04-25 |
Chugai Seiyaku Kabushiki Kaisha |
Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
|
EP3536712B1
(en)
|
2011-09-16 |
2023-05-31 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
|
MX354988B
(es)
|
2011-10-25 |
2018-03-28 |
Prothena Biosciences Ltd |
Formulaciones de anticuerpo y metodos.
|
CN108771655A
(zh)
|
2011-10-28 |
2018-11-09 |
诚信生物公司 |
含有氨基酸的蛋白质制剂
|
MX363226B
(es)
|
2011-10-31 |
2019-03-15 |
Genentech Inc |
Formulaciones de anticuerpos.
|
JP2014532713A
(ja)
|
2011-11-02 |
2014-12-08 |
ハルシオン,インコーポレイテッド |
創傷処置の方法及び組成物
|
US9737662B2
(en)
|
2011-11-07 |
2017-08-22 |
Battelle Memorial Institute |
Processes for delivery of viscous drug therapies
|
EP2596796B1
(en)
*
|
2011-11-24 |
2013-11-13 |
Quimera Ingenieria Biomedica, S.L. |
Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures
|
EP2793940B1
(en)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
EP2797953B1
(en)
|
2011-12-28 |
2020-06-03 |
Amgen Inc. |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
SG11201403792TA
(en)
|
2012-01-23 |
2014-10-30 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
US9144646B2
(en)
|
2012-04-25 |
2015-09-29 |
Fresenius Medical Care Holdings, Inc. |
Vial spiking devices and related assemblies and methods
|
BR112014028600B1
(pt)
|
2012-05-18 |
2022-11-22 |
Genentech, Inc |
Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
EP2859018B1
(en)
|
2012-06-06 |
2021-09-22 |
Zoetis Services LLC |
Caninized anti-ngf antibodies and methods thereof
|
NZ702342A
(en)
*
|
2012-06-21 |
2016-07-29 |
Ucb Pharma Sa |
Pharmaceutical formulation
|
AU2013285488B2
(en)
|
2012-07-05 |
2018-03-22 |
Ucb Pharma S.A. |
Treatment for bone diseases
|
US9221904B2
(en)
|
2012-07-19 |
2015-12-29 |
National Cheng Kung University |
Treatment of osteoarthritis using IL-20 antagonists
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
FR2994390B1
(fr)
*
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
KR102238677B1
(ko)
|
2012-09-07 |
2021-04-12 |
코히러스 바이오사이언시즈, 인코포레이티드 |
아달리무맙의 안정한 수성 제형
|
FR2995214B1
(fr)
|
2012-09-10 |
2014-11-21 |
Adocia |
Solution a viscosite reduite de proteine a concentration elevee
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
US9474803B2
(en)
*
|
2012-11-27 |
2016-10-25 |
Alteogen Inc. |
Composition for stabilizing fusion protein in which protein and FC domain are fused
|
WO2014141149A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations with reduced viscosity
|
CN111529708A
(zh)
|
2013-03-15 |
2020-08-14 |
夏尔维洛药品公司 |
用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
WO2015000865A1
(en)
|
2013-07-04 |
2015-01-08 |
F. Hoffmann-La Roche Ag |
Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
EP3791862A1
(en)
|
2013-09-11 |
2021-03-17 |
Eagle Biologics, Inc. |
Liquid protein formulations containing viscosity-lowering agents
|
BR112016006197B1
(pt)
|
2013-09-27 |
2023-04-11 |
Chugai Seiyaku Kabushiki Kaisha |
Método para produzir um anticorpo biespecífico de polipeptídeos
|
KR20160081978A
(ko)
|
2013-11-12 |
2016-07-08 |
사노피 바이오테크놀로지 |
Pcsk9 억제제의 사용을 위한 투약 요법
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
BR112016025312A2
(pt)
|
2014-05-01 |
2017-10-17 |
Genentech Inc |
variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
US20160074515A1
(en)
*
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
PL3169353T3
(pl)
|
2014-07-16 |
2020-06-01 |
Sanofi Biotechnology |
SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
|
KR102486321B1
(ko)
|
2014-07-18 |
2023-01-09 |
사노피 |
암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
TW201628649A
(zh)
|
2014-10-09 |
2016-08-16 |
再生元醫藥公司 |
減少醫藥調配物中微可見顆粒之方法
|
RU2017111228A
(ru)
*
|
2014-10-18 |
2018-11-21 |
Пфайзер Инк. |
Композиции антитела против IL-7R
|
CA2960797A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
JP2017537084A
(ja)
|
2014-11-12 |
2017-12-14 |
トラコン ファーマシューティカルズ、インコーポレイテッド |
抗エンドグリン抗体及びその用途
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
WO2016120753A1
(en)
|
2015-01-28 |
2016-08-04 |
Pfizer Inc. |
Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
|
EP3319930A4
(en)
*
|
2015-07-07 |
2019-04-10 |
NanoBio Corporation |
METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS
|
GB2556002B
(en)
*
|
2015-07-07 |
2020-12-16 |
Bluewillow Biologics Inc |
Methods and compositions for nanoemulsion vaccine formulations
|
US20170007690A1
(en)
*
|
2015-07-07 |
2017-01-12 |
Nanobio Corporation |
Methods and compositions for the stabilization of anthrax recombinant protective antigen
|
SG10202101105XA
(en)
|
2015-08-13 |
2021-03-30 |
Amgen Inc |
Charged depth filtration of antigen-binding proteins
|
CA2995645A1
(en)
|
2015-08-18 |
2017-02-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
EP3368074A2
(en)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-factor d antibodies and conjugates
|
EP3368090A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody variant conjugates and uses thereof
|
WO2017115773A1
(ja)
|
2015-12-28 |
2017-07-06 |
中外製薬株式会社 |
Fc領域含有ポリペプチドの精製を効率化するための方法
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
WO2017184880A1
(en)
|
2016-04-20 |
2017-10-26 |
Coherus Biosciences, Inc. |
A method of filling a container with no headspace
|
RU2748046C2
(ru)
|
2016-04-28 |
2021-05-19 |
Чугаи Сейяку Кабусики Кайся |
Препарат, содержащий антитело
|
ES2770674T3
(es)
|
2016-06-10 |
2020-07-02 |
Octapharma Ag |
Composición de inmunoglobulinas de alta concentración para aplicaciones farmacéuticas
|
US20190175683A1
(en)
|
2016-08-05 |
2019-06-13 |
Csl Behring Gmbh |
Pharmaceutical formulations of c1 esterase inhibitor
|
KR102369014B1
(ko)
|
2016-08-16 |
2022-03-02 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
CA3035327A1
(en)
|
2016-09-06 |
2018-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
|
MX2019004580A
(es)
|
2016-10-21 |
2019-08-12 |
Amgen Inc |
Formulaciones farmaceuticas y metodos para prepararlas.
|
PL3532838T3
(pl)
|
2016-10-25 |
2022-10-03 |
Regeneron Pharmaceuticals, Inc. |
Metody i systemy analizy danych chromatograficznych
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
CA3060581A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
JP7263320B2
(ja)
|
2017-08-22 |
2023-04-24 |
バイオジェン・エムエイ・インコーポレイテッド |
抗ベータアミロイド抗体を含有する医薬組成物
|
MX2020002710A
(es)
|
2017-09-29 |
2020-07-20 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo.
|
KR20200138254A
(ko)
|
2018-03-30 |
2020-12-09 |
암젠 인크 |
C-말단 항체 변이체
|
EP3928765A1
(en)
*
|
2018-04-16 |
2021-12-29 |
Merck Patent GmbH |
Viscosity reduction of highly concentrated protein formulations
|
JP7235770B2
(ja)
|
2018-05-10 |
2023-03-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
高濃度vegf受容体融合タンパク質を含む製剤
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
IL267923B2
(en)
*
|
2018-08-02 |
2023-06-01 |
Grifols Worldwide Operations Ltd |
The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
|
EP4021497A4
(en)
*
|
2019-08-30 |
2023-09-06 |
Kashiv Biosciences, LLC |
NOVEL FORMULATION OF A HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODIES
|
EP3808777A1
(en)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stable liquid antibody formulations
|
KR20230038752A
(ko)
|
2020-07-13 |
2023-03-21 |
메르크 파텐트 게엠베하 |
고농축 단백질 제형을 위한 점도 감소 부형제 및 이들의 조합
|
IL300133A
(en)
|
2020-07-31 |
2023-03-01 |
Genentech Inc |
Anti-integrin antibody compositions in cell 7 and devices
|
WO2023175035A1
(en)
*
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|